[A型肉毒杆菌毒素二线治疗失败的耳鼻喉科患者首次使用B型肉毒杆菌毒素]

[First use of botulinum toxin type B in ENT patients with secondary therapy failure of botulinum toxin type A].

作者信息

Guntinas-Lichius O

机构信息

Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Kopf- und Hals-Chirurgie, Universität zu Köln.

出版信息

HNO. 2004 Jan;52(1):53-6. doi: 10.1007/s00106-003-0844-8. Epub 2003 Jun 17.

DOI:10.1007/s00106-003-0844-8

PMID:14740116

Abstract

The first botulinum toxin type B (BT-B) formulation, NeuroBloc, has been licensed in Germany for the treatment of cervical dystonia since March 2001. This allows the treatment of patients with secondary failure of botulinum type A (BT-A) injections for the first time. Three patients with such a secondary failure were successfully treated with BT-B. A total of 1,000 mouse units (MU) NeuroBloc per eye were injected in a patient with blepharospasm. The treatment was effective for 4 months. In a patient with spasmodic dysphonia, 250 MU were injected into each vocal cord. This was effective for 3.5 months. The third patient suffered from bilateral Frey's syndrome. A total of 7,500 MU were used on the right side and 6,000 MU on the left side to stop the gustatory sweating for 9 months. Overall, BT-B showed similar intervals of effectiveness as BT-A. Side effects were not seen using the above dosage regimes.

摘要

首款B型肉毒毒素（BT - B）制剂NeuroBloc自2001年3月起在德国获得治疗颈部肌张力障碍的许可。这首次使得A型肉毒毒素（BT - A）注射继发性失效的患者能够得到治疗。三名出现这种继发性失效情况的患者接受BT - B治疗取得成功。一名眼睑痉挛患者每只眼睛注射了总计1000鼠单位（MU）的NeuroBloc。治疗效果持续了4个月。一名痉挛性发音障碍患者每侧声带注射了250 MU。这一治疗效果持续了3.5个月。第三名患者患有双侧弗雷氏综合征。右侧总共使用了7500 MU，左侧使用了6000 MU，从而抑制味觉性出汗达9个月。总体而言，BT - B显示出与BT - A相似的有效时长。采用上述剂量方案未观察到副作用。